Invitrogen™ Envafolimab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA542259	100 μg

Catalog No. PIMA542259 Supplier Invitrogen™ Supplier No. MA542259

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt. Isotype of this product is: (VH-CH2-CH3)2.

Envafolimab (KN035) is the world's first new fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc. Compared with the PD-1/PD-L1 antibodies currently on the market and under development, it has a distinct advantage . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and fast tumor penetration, which can improve the compliance of tumor patients and improve the quality of life of patients, which is in line with the future trend of long-term management of tumors as chronic diseases.

Specifications

• Antigen: Envafolimab Humanized
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 2.8 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: KN-035
• Host Species: Human
• Immunogen: Human CD274/PD-L1/B7-H1.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: VH-VH
• Target Molecule: Chemical